clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Buruli Ulcer D054312 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fichtenbaum CJ et al. Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. 2001 AIDS pmid:11546956
Holmberg SD and Moorman AC Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. 2001 AIDS pmid:11504998
Chaisson RE et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. 1997 AIDS pmid:9147422
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Hewitt RG et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. 1999 AIDS pmid:10449290
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. 2000 AIDS pmid:11153670
High-dose clarithromycin should be avoided. 1996 AIDS Alert pmid:11363723
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
New drug applications sought. 1995 AIDS Alert pmid:11362777
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925
Clarithromycin for MAC. 1995 AIDS Patient Care pmid:11361361
Rosales CM et al. AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. 2002 AIDS Patient Care STDS pmid:12542930
Mah Ming JB and Gill MJ Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. 2003 AIDS Patient Care STDS pmid:12816614
Monno R et al. Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. 2001 AIDS Patient Care STDS pmid:11788074
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Desimone JA et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. 2003 AIDS Patient Care STDS pmid:14746655
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. 1996 AIDS Patient Care STDS pmid:11361534
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. 1996 AIDS Patient Care STDS pmid:11361575
Clarithromycin and MAC. 1996 AIDS Patient Care STDS pmid:11361673
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Aboulafia DM Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. 2003 AIDS Read pmid:14524324
Kahlon SS et al. Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. 2008 AIDS Read pmid:18975441
Chu J et al. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 2011 AIDS Res Ther pmid:21388558
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Savarino V et al. OAM for cure of Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10930908
Perri F et al. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? 2001 Aliment. Pharmacol. Ther. pmid:11421877
Perri F et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. 2001 Aliment. Pharmacol. Ther. pmid:11421878
Pilotto A et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. 2001 Aliment. Pharmacol. Ther. pmid:11421879
Molina-Infante J et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. 2015 Aliment. Pharmacol. Ther. pmid:25776067
Gasbarrini A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:10632649
Chan FK et al. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. 2000 Aliment. Pharmacol. Ther. pmid:10632651
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Vakil N et al. Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. 2008 Aliment. Pharmacol. Ther. pmid:18774949
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Labenz J et al. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. 1997 Aliment. Pharmacol. Ther. pmid:9042978
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Di Caro S et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:11876707
Wu JC et al. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. 2002 Aliment. Pharmacol. Ther. pmid:11876709
Savarino V et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:9892878
Pozzato P et al. Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9663724
Goh KL et al. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? 1997 Aliment. Pharmacol. Ther. pmid:9663838
Kolkman JJ et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9663840
You JH et al. Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. 2001 Aliment. Pharmacol. Ther. pmid:11421876
Vcev A et al. Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. 2000 Aliment. Pharmacol. Ther. pmid:10632647
Sengupta S et al. Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. 2006 Aliment. Pharmacol. Ther. pmid:16803607
Osato MS et al. Comparative efficacy of new investigational agents against Helicobacter pylori. 2001 Aliment. Pharmacol. Ther. pmid:11284777
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
McNulty CA et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? 2012 Aliment. Pharmacol. Ther. pmid:22469191